The Cannabist Company Holdings, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA13765Y1034
CAD
0.04
-0.02 (-33.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About The Cannabist Company Holdings, Inc. stock-summary
stock-summary
The Cannabist Company Holdings, Inc.
Pharmaceuticals & Biotechnology
Columbia Care Inc is a provider of cannabis-based health and wellness solutions. The Company is engaged cultivating, manufacturing and providing medical and adult use cannabis products and related services with licenses in over 18 the United States jurisdictions and the European Union (EU). The Company operates over 108 facilities including 81 dispensaries and 27 cultivation and manufacturing facilities. The Company operates as the original providers of medical cannabis in the United States and continues to deliver a patient-centered medicinal cannabis operation. The company offers products spanning flower, edibles, oils, and tablets, and manufactures brands including Seed & Strain, Amber and Platinum Label Cannabidiol (CBD) products.
Company Coordinates stock-summary
Company Details
680 Fifth Ave., 24th Floor , NEW YORK NY : 10019
stock-summary
Tel: 1 416 86973681 121 2710915
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 8 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Michael Abbott
Executive Chairman of the Board
Mr. Nicholas Vita
Chief Executive Officer, Director
Mr. Jeffrey Clarke
Independent Director
Mr. Igor Gimelshtein
Independent Director
Mr. James Kennedy
Independent Director
Mr. Jonathan May
Independent Director
Mr. Frank Savage
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
120 Million
(Quarterly Results - Jun 2025)
Net Profit:
-107 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 56 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-2.13

stock-summary
Return on Equity

98.35%

stock-summary
Price to Book

-0.30